

Magle Chemoswed submits updated Technical File for approval of its SmartGel wound hydrogel medical device

Magle Chemoswed announces that the Company submitted a final medical device Technical File to the appointed European Notified Body for CE mark approval of its SmartGel product. SmartGel is a non-allergenic chronic wound hydrogel based on the Company's unique microsphere technology, following initial review from the Notified Body in April 2020. SmartGel contains a known antimicrobial suspended in the biodegradable starch microspheres for optimal infection prevention and treatment in chronic wounds. SmartGel is proven to deliver moisture to the wound while maintaining enough absorption capacity for exudate, debris and bacteria.

"I am very proud of the team's dedication in responding to the Notified Body's initial review of the final Technical File. This is another major milestone for Magle Chemoswed and is further strong evidence of the versatility of our technology platform," says Justin Pierce CEO of Magle Chemoswed.

Contacts

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

About Us

We are Magle Chemoswed, a Malmö-based contract development and manufacturing organization (CDMO) that serves companies in the pharmaceutical and medical device industry on a contract basis. We provide comprehensive services from product development through product manufacturing and we pride ourselves in coming up with solutions to complex healthcare challenges. Together with our customers, we take innovations from idea to product. Learn more on www.maglechemoswed.com.

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[Magle Chemoswed submits updated Technical File for approval of its SmartGel wound hydrogel medical device](#)